-
Family planning clinicians have new research information to add to their emergency contraception (EC) knowledge bank as they incorporate use of two new branded products into their practice.
-
In 2007, the Centers for Disease Control and Prevention reported that 26% of HIV/AIDS diagnoses among adolescents and adults were among females.
-
A healthy, nonsmoking woman, age 36, waits in your examination room. While she has been married for seven years, she and her husband are not yet ready to begin their family. What contraceptive choices are available to her?
-
The HIV community has been asking since 1982: "How might we go about encouraging condom use in discordant couples?" On the whole, our efforts have been a disappointing failure.
-
If your facility provides comprehensive sexually transmitted disease care for men who have sex with men (MSM), be sure to incorporate new guidance from the Centers for Disease Control and Prevention (CDC) regarding gonorrhea and chlamydia testing.
-
Women who want a permanent form of birth control now have a new option. The Food and Drug Administration (FDA) has approved the Adiana permanent contraception system, manufactured by Hologic of Bedford, MA.
-
Findings from new research may aid clinicians in identifying women who are likely to gain weight while using depot medroxyprogesterone acetate (DMPA, Depo Provera). Research indicates that DMPA users whose weight increased by 5% within the first six months of use are at risk of continued, excessive weight gain.
-
With the wide array of birth control options available today, are adolescents still relying on coitus interruptus? Results of a 2009 study indicate that clinicians should not consider use of contraceptive withdrawal infrequent among teens.
-
After taking the necessary diagnostic steps, the results are clear: The patient sitting in front of you needs to be treated for bacterial vaginosis (BV). The most common vaginal infection in women of childbearing age, women with BV may present with a white or gray discharge, odor, pain, or burning during urination. Symptoms aren't always present, though. More than 50% of women with BV may be asymptomatic.
-
Two new programs have been announced by Merck & Co. to help confirm patients' insurance coverage and address providers' reimbursement concerns regarding Gardasil, the quadrivalent human papillomavirus (HPV) vaccine.
